Back to top
more

First Trust Health Care AlphaDEX ETF: (FXH)

(Real Time Quote from BATS) As of Aug 5, 2025 09:56 AM ET

$100.19 USD

100.19
3

-0.28 (-0.28%)

Volume: 3

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

Zacks News

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Sanghamitra Saha headshot

Stocks Near Record Highs: Buy 6 Top-Ranked ETFs at Cheap Valuation

Wall Street has rallied hard lately on vaccine distribution, decent corporate earnings and strong cash pile-up at the household and corporate levels.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Sanghamitra Saha headshot

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Sanghamitra Saha headshot

Time for Pharma and Healthcare ETFs?

The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales

Sanghamitra Saha headshot

2 Sector ETFs Hovering Around All-Time Highs

The U.S. economic backdrop and investors' sentiments have remained mixed in recent weeks.

Sanghamitra Saha headshot

Are Healthcare ETFs Poised for a Comeback?

Decent earnings growth picture and valuation as well as solid deals activities have been favoring healthcare sector at the current level.